Common Treatment Formulation for Non-Scaring (Androgenetic) Alopecia

Yıl 2023, Cilt: 6 Sayı: 1, 56 - 63, 01.07.2023

Jannat Al-jubouri Leyla Beba Pojarani Metin Celik

https://doi.org/10.54994/emujpharmsci.1211611

Öz

In spite of being a non-life-threatening condition, hair loss (alopecia) severely impacts the quality of life of individuals who experience it. Recent studies indicate that the number of patients suffering from alopecia globally is on the rise. Androgenic alopecia (AGA) affects both genders at all ages. Genetic factors and family history are found to greatly impact the likelihood of experiencing hair loss. Statistics reveal that during the course of their lives, 80% of men experience alopecia, while 40 to 50% of women are likely to face some form of hair shedding. AGA is characterized by frontal-temporal hair shedding in men and hair thinning of the midline part of the scalp for women. A variety of herbal formulations are available on the market to combat AGA, while only two FDA-approved medications exist at the moment: oral finasteride and topical minoxidil. Topical formulations of finasteride are still under clinical trials. Minoxidil and finasteride formulations provide effective AGA treatment for both genders. Recent concerns regarding potential side effects of these two medications have drawn interest in providing new innovative alternative formulations (nutrients, minerals and vitamins) to provide a safer treatment against AGA. This article provides a brief overview of the current and alternative AGA formulations.

Anahtar Kelimeler

AGA, Alopecia, Finasteride, Hair Loss, Minoxidil

Kaynakça

• Al Aboud AM, Zito PM (2019). Alopecia, Conn’s Handb. Model. Hum. Aging, 751–762.
• Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A (2019). The Role of Vitamins and Minerals in Hair Loss: A Review, Dermatol. Ther. (Heidelb). 9: 51–70.
• Araújo R, Fernandes M, Cavaco-Paulo A, Gomes A (2011). Biology of human hair: Know your hair to control it, Adv. Biochem. Eng. Biotechnol. 125: 121–143.
• Ashique S, Sandhu NK, Haque SN, Koley K (2020). A Systemic Review on Topical Marketed Formulations, Natural Products, and Oral Supplements to Prevent Androgenic Alopecia: A Review, Nat. Products Bioprospect. 10: 345–365.
• Bates JM, Spate VL, Steven MJ, Germain DL, Galton VA (2000). Effects of selenium deficiency on tissue selenium content, deiodinase activity, and thyroid hormone economy in the rat during development, Endocrinology 141: 2490–2500.
• DeVillez RL (1994). Androgenetic Alopecia in the Female, Arch. Dermatol. 130: 303.
• Ezekwe N, King M, Hollinger JC (2020). The Use of Natural Ingredients in the Treatment of Alopecias with an Emphasis on Central Centrifugal Cicatricial Alopecia: A Systematic Review, J. Clin. Aesthet. Dermatol. 13: 23.
• Gubelin W, Harcha J, Barboza M, Tsai TF, Katsuoka K, et al. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia, J. Am. Acad. Dermatol. 70: 489-498.e3.
• Guo S, Lilly P, Siervogel RM, Cam P, E Lea and P. D, P r e v a l e n c e o f M a l e, 0512 (1998), pp. 1330–1332.
• Hosking AM, Juhasz M, Atanaskova MN (2019). Complementary and Alternative Treatments for Alopecia: A Comprehensive Review, Ski. Appendage Disord. 5: 72–89.
• Kelly Y, Blanco A, Tosti A (2016). Androgenetic Alopecia: An Update of Treatment Options, Drugs 76: 1349–1364.
• Levy LL, Emer JJ (2013). Female pattern alopecia: Current perspectives, Int. J. Womens. Health 5: 541–556.
• Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. (2017). Androgenetic alopecia: a review, Endocrine 57: 9–17.
• Messenger AG, Rundegren J (2004). Minoxidil: Mechanisms of action on hair growth, Br. J. Dermatol. 150: 186–194.
• Nabahin A, Eloun AA, Naser SSA (2017). Expert System for Hair Loss Diagnosis and Treatment, Int. J. Eng. Inf. Syst. 1 :160–169.
• Nickel JC (2004). Comparison of clinical trials with finasteride and dutasteride. Reviews in urology, 6(9): 31–39.
• Olszewska M, Rudnicka L (2005). Effective treatment of female androgenic alopecia with dutasteride, undefined.
• Phillips TG, Slomiany WP, Allison R (2017). Hair Loss: Common Causes and Treatment, Am. Fam. Physician 96: 371–378.
• Sadick NS (2018). New-Generation Therapies for the Treatment of Hair Loss in Men, Dermatol. Clin. 36: 63–67.
• Sharquie KE, Al-Obaidi HK (2002). Onion juice (Allium cepa L.), a new topical treatment for alopecia areata, J. Dermatol. 29: 343–346.
• S.W. Lee, M. Juhasz, P. Mobasher, Ekelem C, Mesinkovska NA (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women, J. Drugs Dermatol. 17: 457.
• Varothai S, Bergfeld WF (2014). Androgenetic alopecia: An evidence-based treatment update, Am. J. Clin. Dermatol. 15: 217–230.
• Völker JM, Koch N, Becker M, Klen A (2020). Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review, Skin Pharmacol. Physiol. 33: 153–169.
• Whiting DA (1999). Dermatopathology of common hair problems, J. Cutan. Med. Surg. 3: 2–13.
• Yip L, Rufaut N, Sinclair R (2011). Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know, Australas. J. Dermatol. 52: 81–88
• York K, Meah N, Bhoyrul B, Sinclair R (2020). Treatment review for male pattern hair-loss, Expert Opin. Pharmacother. 21: 603–612.
• Zins GR (1988). The history of the development of minoxidil, Clin. Dermatol. 6: 132–147.